NCT
HOME CURRENT ARCHIVE COVID-19
HOME CURRENT ARCHIVE PUBLISH INSTRUCTIONS
FOR AUTHORS COVID-19 LOG IN / REGISTER HISTORY ABOUT US DIRECTORY CONTACT
Photodynamic therapy, a new variety of

José Julián Alcocer-Macías, Jorge Cogordán Coló





2000, Number 3

2000; 59 (3)






ABSTRACT

The development of photodynamic therapy (PDT) has provided a new method for local treatment in esophageal and lung cancer as well as in other malignancies in the skin, head and neck. The photodynamic therapy involves a photosensitizing agent (photofrin), which when exposed to light of the proper wavelength (laser), forms toxic oxygen radicals that result in cell death. This method is technically easy to perform, with local or general anesthesia and decreased risk of complications.

KEYWORDS

Photodynamic therapy, laser, photofrin.

REFERENCES

  1. Raab O. Uber die wirkung fluoreszierenden stoffen. Infusoria Z Biol 1900; 39: 524.

  2. Jesionek A, Tappeiner VH. Zur behandlung der huatcarcinomit mit fluorescierenden stoffen. Muench Med Wochneshr 1903; 47: 2042.

  3. Hausman W. Die sensibilisierende wirkung deshematoporphyrins. Biochem Z 1911; 30: 276.

  4. Lipson RL, Baldes EJ. The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol 1960; 82: 508-516.

  5. Gray M, Lipson RI, Macek JVS et al. Use of hematoporphyrin derivative in detection and management of cervical cancer. Am J Obstet Gynecol 1967; 9: 766-771.

  6. Gregorie HB Jr, Horger EO, Ward JL et al. Hematoporphyrin-derivative fluorescense in malignant neoplasms. Ann Surg 1968; 167: 820-828.

  7. Lipson RL, Baldes EJ, Gray MJ. Hematoporphyrin derivative for detection and management of cancer. Cancer 1967; 20: 2254-2257.

  8. Lipson RL, Baldes EJ, Olsen AM. The use of a derivative of hematoporphyrin in tumor detection. J Natl Cancer Inst 1961; 26: 1-11.

  9. Lipson RI, Gray MJ, Baldes EJ. Hematoporphyrin derivative for detection and management of cancer. In: Proceedings of the 9th International Cancer Congress, Tokyo, Japan 1966: 393.

  10. Dougherty TJ. Grindley GE, Fiel R et al. Photoradiation therapy II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975; 55: 115-121.

  11. Dougherty TJ. Photosensitizers. Therapy and detection of malignant tumors. Photochem Photobiol 1987; 45: 874-889.

  12. Dougherty TJ, Potter WR, Weishaupt KR. The structure of the active component of hematoporphyrin derivative. In: Doiron DR, Gomer CJ (eds). Porphyrin localization and treatment of tumors. New York: Alan R Liss 1984: 301.

  13. Bugelski PH, Porter CW, Dougherty TJ. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res 1981; 41: 4606-4612.

  14. Selman SH, Kreimer-Birnbaum M, Klauning JE et al. Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light. Cancer Res 1984; 44: 1924-1927.

  15. Star WM, Marijinissen HP, Van den Berg-Blok AE et al. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 1986; 46: 2532-2540.

  16. Barel A, Jori G, Perin A et al. Role of high, low and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo. Cancer Lett 1986; 32: 145-150.

  17. Bellnier DA, Henderson BW. Determinants for photodynamic tissue destruction. In: Henderson BW, Dougherty TJ (eds). Photodynamic Therapy. New York: Marcel Dekker 1992: 117.

  18. Jori G, Tomio L, Reddi E et al. Preferential delivery of liposome-incorporated porphyrins to neoplastic cells in tumour-bearing rats. Br J Cancer 1983; 48: 307-309.

  19. Pass HI. Photodynamic therapy for lung cancer. Chest Surg Clin North Am 1991; 1: 135-151.

  20. Figgie FHJ, Weiland GS, Manganiello LOJ. Cancer detection and therapy. Affinity of neoplastic embryonic and traumatized tissue for porphyrins and metallo-porphyrins. Proc Soc Exp Biol Med 1948; 68: 640-641.

  21. Gomer CJ, Dougherty TJ. Determination of [3H] and [14C] hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res 1979; 39: 146-151.

  22. Kaye AH, Morstyn G, Ashcroft RG. Uptake and retention of hematoporphyrin derivative in an in vivo/in vitro model of cerebral glioma. Neurosurgery 1985; 17: 883-890.

  23. Kessel D. Effects of photoactivated porphyrins at the cell surface of leukemia L 1210 cells. Biochemistry 1977; 16: 3443-3449.

  24. Cortese DA, Kinsey JH, Woolner LB et al. Hematoporphyrin derivative in the detection of radiographically occult lung cancer. Am Rev Respir Dis 1982, 126: 1087-1088.

  25. Tochner Z, Mitchell JB, Smith P et al. Photodynamic therapy of ascites tumors within the peritoneal cavity. Br J Cancer 1986; 53: 733-736.

  26. Lee S, Forbes IJ, Betts WH. Oxigen dependency of photocytotoxicity with haematoporphyrin derivative. Photochem Photobiol 1984; 39: 631-634.

  27. Mitchell JB, McPherson S, DeGraff W et al. Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of chinese hamster cells. Cancer Res 1985; 45: 2008-2011.

  28. Jamieson CH, McDonald WN, Levy JG. Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells. Leuk Res 1990; 14: 209-219.

  29. Pope AJ, Masters W, Macrobert AJ. The photodynamic effect of a pulsed dye laser on human bladder carcinoma cells in vitro. Urol Res 1990; 18: 267-270.

  30. Andreoni A, Cubeddu R, DeSilvestri S et al. Effects of laser irradiation on hematoporphyrin-treated normal transformed thyroid cells in culture. Cancer Res 1983; 43: 2076-2080.

  31. Borrelli MJ, Wong RSL, Dewey WC. A direct correlation between hyperthermia induced bleeding and survival in synchronous G, CHO cells. J Cell Physiol 1986; 126: 181-190.

  32. Volden G, Christensen T, Moan J. Photodynamic membrane damage of hematoporphyrin in derivative treated NHIK 3025 cell in vitro. Photobiochem Photobiophys 1981; 3: 105.

  33. Hilf R, Murant RS, Narayanan U et al. Hematoporphyrin derivative-induced photosensitivity of mitochondrial succinate dehydrogenase and selected cytosolic enzymes of R3230AC mammary adenocarcinomas of rats. Cancer Res 1984; 44: 1483-1488.

  34. Wieman TJ, Mang TS, Fingar VS et al. Effect of photodynamic therapy on blood flow in normal and tumor vessels. Surgery 1988; 104: 512-517.

  35. Fingar VH, Wieman TJ, Doak KW. Role of thromboxane and prostacycline release on phothodynamic therapy-induced tumor destruction. Cancer Res 1990; 50: 2599-2603.

  36. Dodd NJ, Moore JV, Poppitt DG et al. In vivo magnetic resonance imaging of the effects of photodynamic therapy. Br J Cancer 1989; 60: 164-167.

  37. Mattiello J, Evelhoch JL, Brown E et al. Effect of photodynamic therapy on RIF-I tumor metabolism and blood flow examined by 31 P and 2H NMR spectroscopy. NMR Biomed 1990; 3: 64-67.

  38. Pass HI. Photodynamic therapy in oncology. Mechanisms and clinical use. J Natl Cancer Inst 1993; 85: 443-456.

  39. Heier SK. Photodynamic therapy for esophageal malignancies. In: Barkin JS, O’Phelan CA (eds). Advanced therapeutic endoscopy, 2nd ed. New York: Raven Press 1994: 57-65.

  40. Marcon NE. Photodynamic therapy and cancer of the esophagus. Semin Oncol 1994; 21 (suppl 15): 20-23.

  41. McCaughan JS Jr. Photodynamic therapy of endobronchial and esophageal tumors, an overview. J Clin Laser Med Surg 1996; 14: 223-233.

  42. Furuse K, Fukuoka M, Kato H et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. J Clin Oncol 1993; 11: 1852-1857.

  43. Overholt BF, Panjehpour M. Photodynamic therapy for Barrett’s esophagus: clinical update. Am J Gastroenterol 1996, 91: 1719-1789.

  44. Pass HI. Photodynamic therapy in oncology. Mechanisms and clinical use. J Natl Cancer Inst 1993; 85: 443-456.


2000, Number 3

2000; 59 (3)